

## NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE

## Health Technology Appraisal

## Docetaxel for hormone-refractory prostate cancer

## Response to consultee and commentator comments on the provisional matrix of consultees and commentators

<b>Technical Lead:</b> Zoe Charles		<b>Executive Lead:</b> Peter Littlejohns		<b>Project Manager:</b> Nina Pinwill	
<b>Version of matrix of consultees and commentators reviewed:</b> Provisional matrix of consultees and commentators sent for consultation					
<b>Summary of comments, action taken, and justification of action:</b>					
	Proposed consultee/commentator:	Proposal made by:	Action taken:	Justification:	
1.	Royal College of Radiologists	British Oncology Pharmacy Association (BOPA)	Added	BOPA suggested that if the treatment is compared with radiotherapy then representation from the Royal College of Radiologists would be appropriate. The Institute agreed with this proposal	

## APPENDIX F

2.	British Association of Urological Surgeons	The Prostate Cancer Charity	Added	The Prostate Cancer Charity advised that some urologists [currently a small number]are becoming interested in administering chemotherapy to men with prostate cancer, and therefore it is relevant to involve this organisation. The Institute agreed with this proposal.
3.	British Association of Urological Nurses	The Prostate Cancer Charity	Added	The Prostate Cancer Charity advised that some urologists [currently a small number]are becoming interested in administering chemotherapy to men with prostate cancer, and therefore it is relevant to involve this organisation. The Institute agreed with this proposal.
4.	BUG, a new special interest grouping of oncologists with an interest in urological cancers	The Prostate Cancer Charity	Queried	The Institute will contact this group to find out if they meet the criteria for inclusion as a consultee or commentator.